Document Detail

Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation.
MedLine Citation:
PMID:  20699617     Owner:  NLM     Status:  MEDLINE    
Tacrolimus (TAC) is an immunosuppressant drug discovered in 1984 by Fujisawa Pharmaceutical Co., Ltd. This drug belongs to the group of calcineurin inhibitors, which has been proven highly effective in preventing acute rejection after transplantation of solid organs. However, neurotoxicity and nephrotoxicity are its major adverse effects. Posterior reversible encephalopathy syndrome (PRES) is the most severe and dramatic consequence of calcineurin inhibitor neurotoxicity. It was initially described by Hinchey et al. in 1996 [N Engl J Med 1996;334:494-450]. Patients typically present with altered mental status, headache, focal neurological deficits, visual disturbances, and seizures. Magnetic resonance imaging is the most sensitive imaging test to detect this. With the more deep-going studies done recently, we have learnt more about this entity. It was noted that this syndrome is frequently reversible, rarely limited to the posterior regions of the brain, and often located in gray matter and cortex as well as in white matter. Therefore, in this review, the focus is on the current understanding of clinical recognition, pathogenesis, neuroimaging and management of TAC-associated PRES after solid organ transplantation.
Qisi Wu; Christian Marescaux; Valérie Wolff; Mi-Young Jeung; Romain Kessler; Valérie Lauer; Yangmei Chen
Related Documents :
18275507 - Trends in adult post-kidney transplant immunosuppressive use in australia, 1991-2005.
16827677 - Post-transplant de novo malignancies in renal transplant recipients: the past and present.
21554397 - Over 500 pancreas transplants by a single team in são paulo, brazil.
12153337 - Immunosuppression in renal transplantation: current status and application in developin...
25292187 - Node retraction during patterning of the urinary collecting duct system.
22136377 - Long-term survival in patients with peripheral t-cell non-hodgkin lymphomas after allog...
Publication Detail:
Type:  Journal Article; Review     Date:  2010-08-12
Journal Detail:
Title:  European neurology     Volume:  64     ISSN:  1421-9913     ISO Abbreviation:  Eur. Neurol.     Publication Date:  2010  
Date Detail:
Created Date:  2010-09-03     Completed Date:  2010-12-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0150760     Medline TA:  Eur Neurol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  169-77     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2010 S. Karger AG, Basel.
The Second Affiliated Hospital , Chongqing Medical University, Chongqing, PR China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Immunosuppressive Agents / adverse effects*
Magnetic Resonance Imaging / methods
Neurotoxicity Syndromes / diagnosis,  etiology*,  therapy
Organ Transplantation / methods
Tacrolimus / adverse effects*
Reg. No./Substance:
0/Immunosuppressive Agents; 109581-93-3/Tacrolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Injury of the spino-thalamo-cortical pathway is necessary for central post-stroke pain.
Next Document:  Definitions of types of hearing impairment: a discussion paper.